Skip to main content
Clinical Trials/NCT03782688
NCT03782688
Completed
Not Applicable

Prospective Evaluation of a Virtual Non-invasive Percutaneous Intervention Planner in Patients With Coronary Artery Disease.

Onze Lieve Vrouw Hospital1 site in 1 country127 target enrollmentFebruary 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stable Coronary Artery Disease
Sponsor
Onze Lieve Vrouw Hospital
Enrollment
127
Locations
1
Primary Endpoint
Agreement on post-PCI fractional flow reserve between virtual treatment based on FFRct planner and measured invasive post-PCI fractional flow reserve.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The PRECISE PERCUTANEOUS CORONARY INTERVENTION (PCI) PLAN STUDY is an investigator-initiated, international and multicenter study of patients with an indication for PCI aiming at assessing the agreement and accuracy of the HeartFlow Planner with invasive fractional flow reserve (FFR) as a reference.

Detailed Description

Multicenter study, including 120 patients at 5 centers in Europe and Asia. After identifying the presence of significant coronary stenosis by means of coronary angiography and invasive fractional flow reserve (FFR≤0.80) the patients will undergo the following procedures: Invasive FFR with intravenous adenosine (i.e. pre- and post-PCI). Optical coherence tomography-guided PCI (i.e. pre- and post-procedural imaging). PCI with newer generation drug-eluting stent.

Registry
clinicaltrials.gov
Start Date
February 1, 2019
End Date
December 18, 2021
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Onze Lieve Vrouw Hospital
Responsible Party
Principal Investigator
Principal Investigator

Jeroen Sonck

Co-Director Cardiovascular Center OLV-Aalst

Onze Lieve Vrouw Hospital

Eligibility Criteria

Inclusion Criteria

  • Coronary artery disease in a major epicardial vessel with an invasive fractional flow reserve (FFR) ≤0.80
  • An indication to Percutaneous coronary intervention

Exclusion Criteria

  • Angiographic exclusion criteria
  • Severely calcified lesion/vessel
  • Bifurcation lesions.
  • Ostial lesions.
  • Left main disease.
  • Severe vessel tortuosity.
  • Clinical exclusion criteria
  • Chronic obstructive pulmonary disease
  • Contraindication to adenosine
  • NYHA class III or IV, or last known left ventricular ejection fraction \<30%

Outcomes

Primary Outcomes

Agreement on post-PCI fractional flow reserve between virtual treatment based on FFRct planner and measured invasive post-PCI fractional flow reserve.

Time Frame: The primary endpoint will be assessed immediately after the procedure (PCI).

The agreement will be assessed by Bland Altman method

Study Sites (1)

Loading locations...

Similar Trials